Literature DB >> 4281879

The effect of saluretics and spironolactone on aldosterone production and electrolyte excretion in man.

H C Erbler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4281879     DOI： 10.1007/bf00501608

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  8 in total

1.  [Treatment of essential hypertension with spironolactone with reference to the plasma renin activity].

Authors:  I Esch; P Placheta
Journal:  Wien Klin Wochenschr       Date:  1973-06-08       Impact factor: 1.704

2.  Selective inhibition of aldosterone synthesis by 11-hydroxylated spirolactone in rat adrenals.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

3.  Stimulation of aldosterone production in vitro and its inhibition by spironolactone.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

4.  On the mechanism of the inhibitory action of the spirolactone SC 9376 (aldadiene) on the production of corticosteroids in rat adrenals in vitro.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

Review 5.  [Clinical pharmacology of diuretics].

Authors:  H Holzgreve
Journal:  Internist (Berl)       Date:  1971-08       Impact factor: 0.743

Review 6.  [Renal action mechanism of diuretics].

Authors:  K Meng
Journal:  Dtsch Med Wochenschr       Date:  1970-10-09       Impact factor: 0.628

7.  Effect of angiotensin and of frusemide on plasma aldosterone, corticosterone, cortisol and renin in man.

Authors:  R Fraser; V H James; J J Brown; P Isaac; A F Lever; J I Robertson
Journal:  Lancet       Date:  1965-11-13       Impact factor: 79.321

8.  Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading.

Authors:  G H Williams; J P Cain; R G Dluhy; R H Underwood
Journal:  J Clin Invest       Date:  1972-07       Impact factor: 14.808
  8 in total
  8 in total

1.  Long term effect of timolol and hydrochlorothiazide, or hydrochlorothiazide and amiloride, in essential hypertension.

Authors:  H Castenfors
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

2.  Interference of spironolactone therapy with adrenal steroid metabolism in secondary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; M Schöneshöfer; M L'age; W Oelkers
Journal:  Klin Wochenschr       Date:  1978-04-01

3.  Improved method for comparative evaluation of aldosterone antagonists in healthy man.

Authors:  J Casals-Stenzel; J Schmalbach; W Losert
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

4.  Effect of aldosterone antagonist canrenone on plasma aldosterone concentration and plasma renin activity, and on the excretion of aldosterone and electrolytes by man.

Authors:  H C Erbler; H Wernze; M Hilfenhaus
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

5.  Development of acute tolerance to bumetanide: constant-rate infusion studies.

Authors:  J A Cook; D E Smith
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

6.  Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa.

Authors:  M Aiba; H Suzuki; K Kageyama; M Murai; H Tazaki; O Abe; T Saruta
Journal:  Am J Pathol       Date:  1981-06       Impact factor: 4.307

7.  Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells.

Authors:  D S Loose; E P Stover; D Feldman
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

8.  Spironolactone in thiazide-induced hypokalaemia: variable response between patients.

Authors:  L E Ramsay; J Hettiarachchi
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.